Home

преходен премия обръщане kapos ioannis cardiology пожар предхожда добави към

Cardiovascular Medicine - Collection 2017/6
Cardiovascular Medicine - Collection 2017/6

Tricuspid Regurgitation: Predicting the Need for Intervention, Procedural  Success, and Recurrence of Disease | JACC: Cardiovascular Imaging
Tricuspid Regurgitation: Predicting the Need for Intervention, Procedural Success, and Recurrence of Disease | JACC: Cardiovascular Imaging

Dr. med. Ioannis Kapos | Cardiology Heart Clinic Hirslanden
Dr. med. Ioannis Kapos | Cardiology Heart Clinic Hirslanden

Controlled-Level EVERolimus in Acute Coronary Syndrome (CLEVER-ACS) - A  phase II, randomized, double-blind, multi-center, placebo-controlled trial  - ScienceDirect
Controlled-Level EVERolimus in Acute Coronary Syndrome (CLEVER-ACS) - A phase II, randomized, double-blind, multi-center, placebo-controlled trial - ScienceDirect

Dr. Rebecca T. Hahn, MD | New York, NY | Cardiologist | US News Doctors
Dr. Rebecca T. Hahn, MD | New York, NY | Cardiologist | US News Doctors

Dr. Isaac George, MD | New York, NY | Thoracic Surgeon | US News Doctors
Dr. Isaac George, MD | New York, NY | Thoracic Surgeon | US News Doctors

Ioannis P. Capos - Training Manager Vian S.A. - Vianex SA | LinkedIn
Ioannis P. Capos - Training Manager Vian S.A. - Vianex SA | LinkedIn

Heart Clinic Zurich (Switzerland) | LinkedIn
Heart Clinic Zurich (Switzerland) | LinkedIn

Recordings CMR JOURNAL CLUB
Recordings CMR JOURNAL CLUB

Tricuspid Regurgitation: Predicting the Need for Intervention, Procedural  Success, and Recurrence of Disease - ScienceDirect
Tricuspid Regurgitation: Predicting the Need for Intervention, Procedural Success, and Recurrence of Disease - ScienceDirect

BIR Publications
BIR Publications

Effect of a Strategy of Comprehensive Vasodilation vs Usual Care on  Mortality and Heart Failure Rehospitalization Among Patients With Acute  Heart Failure: The GALACTIC Randomized Clinical Trial. - Abstract - Europe  PMC
Effect of a Strategy of Comprehensive Vasodilation vs Usual Care on Mortality and Heart Failure Rehospitalization Among Patients With Acute Heart Failure: The GALACTIC Randomized Clinical Trial. - Abstract - Europe PMC

Dr. med. Ioannis Kapos | Cardiology Heart Clinic Hirslanden
Dr. med. Ioannis Kapos | Cardiology Heart Clinic Hirslanden

Ioannis Kapos MD | Cardiac Imaging and Cardiology Zurich
Ioannis Kapos MD | Cardiac Imaging and Cardiology Zurich

Dr. med. Ioannis Kapos | Cardiology Heart Clinic Hirslanden
Dr. med. Ioannis Kapos | Cardiology Heart Clinic Hirslanden

Tricuspid Regurgitation: Predicting the Need for Intervention, Procedural  Success, and Recurrence of Disease - ScienceDirect
Tricuspid Regurgitation: Predicting the Need for Intervention, Procedural Success, and Recurrence of Disease - ScienceDirect

Tricuspid Regurgitation: Predicting the Need for Intervention, Procedural  Success, and Recurrence of Disease | JACC: Cardiovascular Imaging
Tricuspid Regurgitation: Predicting the Need for Intervention, Procedural Success, and Recurrence of Disease | JACC: Cardiovascular Imaging

Dr. med. Ioannis Kapos | Cardiology Heart Clinic Hirslanden
Dr. med. Ioannis Kapos | Cardiology Heart Clinic Hirslanden

Recordings CMR JOURNAL CLUB
Recordings CMR JOURNAL CLUB

Heart Valve Center Hirslanden | Heart Clinic Hirslanden Zurich
Heart Valve Center Hirslanden | Heart Clinic Hirslanden Zurich

Recordings CMR JOURNAL CLUB
Recordings CMR JOURNAL CLUB

Controlled-Level EVERolimus in Acute Coronary Syndrome (CLEVER-ACS) - A  phase II, randomized, double-blind, multi-center, placebo-controlled trial  - ScienceDirect
Controlled-Level EVERolimus in Acute Coronary Syndrome (CLEVER-ACS) - A phase II, randomized, double-blind, multi-center, placebo-controlled trial - ScienceDirect

Ioannis Kapos – Medical Doctor – Heart Clinic Zurich (Switzerland) |  LinkedIn
Ioannis Kapos – Medical Doctor – Heart Clinic Zurich (Switzerland) | LinkedIn

Heart Clinic Hirslanden Zurich | Interdisciplinary Heart Team
Heart Clinic Hirslanden Zurich | Interdisciplinary Heart Team

Controlled-Level EVERolimus in Acute Coronary Syndrome (CLEVER-ACS) - A  phase II, randomized, double-blind, multi-center, placebo-controlled trial  - ScienceDirect
Controlled-Level EVERolimus in Acute Coronary Syndrome (CLEVER-ACS) - A phase II, randomized, double-blind, multi-center, placebo-controlled trial - ScienceDirect